Close
  Indian J Med Microbiol
 

Figure 2: Glycemic variability of basal insulin. Within-subject variability in pharmacodynamic endpoints for insulin detemir versus NPH versus glargine and insulin glargine versus degludec in patients with type 1 diabetes undergoing euglycemic clamp trial. The dose administered was 0.4 IU/kg.

Figure 2: Glycemic variability of basal insulin. Within-subject variability in pharmacodynamic endpoints for insulin detemir versus NPH versus glargine and insulin glargine versus degludec in patients with type 1 diabetes undergoing euglycemic clamp trial. The dose administered was 0.4 IU/kg.